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A B S T R A C T
The External Quality Assurance (EQA) in medical microbiology in the Czech Republic is well organized. It is coordi-
nated by the Accreditation Department of the Centre of Epidemiology and Microbiology (AD-CEM) of the National Insti-
tute of Public Health in Prague. Since 1993 when the first samples were sent out the number of programmes and partici-
pating laboratories has been rapidly increasing. EQA for Human papillomavirus (HPV) has been available since 2000.
As has been shown for other programmes, the EQA for HPV has proved to be useful, helping to improve the accuracy of
analyses and contributing to the standardization of methods of HPV DNA testing. EQA for HPV has been well received
by routine laboratories, demonstrated by a high number of these institutions voluntarily participating in EQA.
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Introduction
Today, most diagnostic laboratories are capable of de-
tecting a wide range of infectious agents. The In Vitro Di-
agnostic Industry is committed to bringing an even big-
ger variety of diagnostic assays on the market in the
future. Even though the process of certification of in vi-
tro diagnostics for infectious agents is obligatory, this is
not always a guarantee that the assay is working prop-
erly in the end-user’s laboratory. Especially for very sen-
sitive molecular diagnostic assays, which often straddle
the divide between research and routine, internal and ex-
ternal quality assurance is important. Several institu-
tions worldwide provide panels of reference samples for
the most commonly diagnosed infections. For Human
papillomaviruses (HPV), the first internationally avail-
able panel of samples for quality assurance was offered
by Instand (WHO Collaborating Centre for Quality As-
surance and Standardization in Laboratory Medicine)1 in
2004.
Long Tradition
The system of External Quality Assessment (EQA) in
the Czech Republic was introduced in 1993. The first
programme focused on sera for detection of the hepatitis
B virus and strains of bacteria for identification. From
1993 till 2002 the number of provided surveys increased
from 2 to 34 and the number of participating laboratories
increased from 79 to 440 (Figures 1 and 2). In order to
provide technical support for this programme, a coordi-
nating centre for EQA in medical microbiology was es-
tablished (the Accreditation Department of the Centre of
Epidemiology and Microbiology (AD-CEM), National In-
stitute of Public Health). Since then, AD-CEM has devel-
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Fig. 1. Number of programmes provided by the Accreditation De-
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oped a wide network of national reference laboratories
and some other highly specialized centres, which prepare
samples for EQA2.
AD-CEM distributes the coded samples together with
all required protocols containing detailed instructions.
Each programme has an individual deadline for receiving
the results. AD-CEM sends the protocols with the results
to the contractual laboratory for evaluation. Each partic-
ipating laboratory in this system has a unique identifica-
tion code and the evaluation of results is therefore anon-
ymous. The certificate of participation is issued to all
participants who registered for the programme in the
particular year and those who successfully passed the
EQA also obtain the Certificate of proper diagnostics.
After ten years of its existence, AD-CEM has achieved
some very positive outcomes. First of all, the accuracy of
analyses has increased and methods have become better
standardized. In addition, significant variations have
been detected between different diagnostic sets; as a re-
sult, those sets that have yielded unsatisfactory results
have been eliminated.
Participation in the system of EQA is not compulsory,
but most of the routine laboratories voluntarily take part
since it allows them to compare the performance of a
wide variety of detection techniques and diagnostic sets
with many others laboratories. All results are published
in the journal, »Zprávy CEM« (News of CEM), issued by
the Centre of Epidemiology and Microbiology, National
Institute of Public Health as well as on the websites of
some of the contractual laboratories.
External Quality Assurance for HPV
In 1998, the National Reference Laboratory (NRL)
for Papillomaviruses was established by the National
Public Health Authority on the recommendation of the
Working Group for Virology of the Society for Clinical
Microbiology of the Czech Medical Association JEP to
improve the interpretation of results and disseminate in-
formation concerning the clinical usefulness of HPV
DNA detection among specialists.
Since 2000, 5 EQA sample series have been distrib-
uted annually to each of the participating laboratories
(Figure 3). Since 2003, EQA has also been provided to
laboratories using PCR-based diagnostic kits. EQA is
carried out depending on the diagnostic kit used (i.e. de-
pending on whether the kit detects both low risk [LR]
and high risk [HR] HPV types or HR HPV types only). If
the kit used detects both LR and HR HPV types, the par-
ticipating laboratory is awarded a score of 2 points for
each correct result and loses 1 point when failing to de-
tect either LR or HR HPV types. When an incorrect re-
sult is reported for a sample with a borderline amount of
virus for a detection limit of the given kit (provided the
test is recommended for diagnostic use by the NRL),
NRL requires correct interpretation of any equivocal re-
sult. If possible, NRL informs the participating labora-
tory about the mechanism likely to be responsible for the
error (e.g. low sensitivity of the method, defective kit
batch, improper performance of the test, sample contam-
ination, etc.).
The samples for EQA are prepared to simulate the
cervical smear samples taken to a transport medium. At
the beginning of EQA, the Specimen Transport Medium
(STM, Digene) was used. Later, when PCR-based com-
mercially available sets appeared, samples prepared in
the PreservCyt medium (Cytyc) for PCR-based methods
were used. Recently, we finished a study whose results
show the possibility of using STM medium for both
non-amplification and amplification-based methods. In
each sample, a background of 100,000 HPV negative cells
is included. Each series contains an HPV negative, LR
HPV positive and HR HPV positive sample and also a
sample positive for both LR and HR HPV. Both HPV pos-
itive cell lines and cloned DNA is used for sample prepa-
ration. Different amounts of HPV positive cells and/or
cloned DNA are used to simulate different viral load and
verify the sensitivity of methods used in laboratories. To
illustrate, we include a table showing the results of par-
ticipating laboratories in 2001 and 2006 (Table 1 and 2)3.
At the beginning of EQA for HPV, most of the labora-
tories used Hybrid Capture Tube test (HCT, Digene),
which has been shown to have a limited sensitivity for











































Fig. 2. Number of laboratories registered in the External Quality
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Fig. 3. Number of laboratories registered and participating in EQA
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the detection of CIN2+ lesions. Therefore, in the EQA in
2000 we set the cut-off line just above the detection level
for HCT. We recommended that all laboratories plan to
switch to HC2 (Digene) (primarily because at that time
no other commercial sets were available on the Czech
market). The reaction was quite positive and as you can
see from Table 3, the spectrum of diagnostic sets used in
routine laboratories changed. In 2000, 50% (11/21) of
laboratories in EQA used HCT, but this number de-
creased to 3 out of 22 in 2002 and just 1 in 23 laboratories
in 2004. 2004 was the first year when 3 laboratories used
PCR-based HPV DNA tests (HPV INNO-LiPA Innogene-
tics, Amplicor HPV Test Roche, DNA PCR Test Gentech).
Discussion
From the onset of EQA, we regularly detected mis-
takes in using even such robust sets as HC2. However,
over the years, the performance of laboratories in EQA
improved and in the last two years we have had no mis-
takes reported from the laboratories using HC2 or HC2
HR sets. In 2006, we had 6 laboratories using commer-
cially available PCR-based sets. The results of EQA from
laboratories which use PCR-based sets show bigger het-
erogeneity and confirm the need for participation in the
EQA (Table 2)3.
In the absence of an internationally available prog-
ramme for EQA for HPV, we exchanged the samples with
the Laboratory of Clinical and Epidemiological Virology,
Rega Institute for Medical Research, University of Leu-
ven, Belgium in 2002. In 2004 Instand (WHO Collabo-
rating Centre for Quality Assurance and Standardization
in Laboratory Medicine)1 for the first time offered EQA
for HPV and since then, NRL has been successfully par-
ticipating in this programme. In 2004, Instand prepared
samples which had a limited amount of HPV DNA (below
the cut-off for HC2 Digene). Since we used different
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TABLE 1

























HCT Digene 26 0.25 0.24 0.33* 0.25 0.25 0.26* 0.73* 0.42* 0.26 0.26* 2.0
HCT Digene 118 0.19 0.25 0.48* 0.26 0.25 0.58* 1.44 1.03 0.34 2.75 6.0
HCT Digene 211 0.58 0.26 0.72* 0.30 0.62 0.35* 1.38 0.64* 0.54 0.31* 2.0
HCT Digene 28 0.23 0.24 0.32* 0.20 0.22 0.34* 0.75* 0.40* 0.20 0.24* 0.0
HCT Digene 371 0.28 0.49 0.39* 0.32 0.25 0.35* 0.77* 0.63* 0.25 1.04 4.0
HCT Digene 406 0.89 1.28** ND ND 0.67 2.01 ND ND 3.33** 0.72* 0.0±4.0
HCT Digene 18 3.78** 3.6** 0.53* 0.99 0.31 0.68* 3.84 1.41 0.29 0.26* 0.0
HCT Digene 192 0.37 0.30 0.45* 0.38 0.37 0.38* 1.07 0.64* 0.43 0.43* 2.0
HC2 Digene 165 0.14 0.17 1.18 0.17 0.19 0.87* 7.02 2.60 0.16 16.89 8–9.0
HC2 Digene 373 0.93 0.19 2.44 0.20 1.14** 1.47 1.81 1.82 0.82 17.93 8.0
HC2 Digene 156 0.18 0.14 1.04 0.15 0.16 1.30 3.42 2.21 0.18 18.90 10.0
HC2 Digene 115 0.20 0.50 1.41 0.16 0.29 1.58 6.30 2.36 0.22 16.78 10.0
HC2 Digene 585 0.54 1.34** 1.88 2.00** 2.12** 2.92 4.71 2.21 5.67** 22.21 2.0
HC2 Digene 584 0.20 0.21 1.42 0.20 0.36 1.38 6.79 3.16 0.20 18.99 10.0
HC2 Digene 13 0.34 0.37 1.75 0.40 0.27 1.38 10.51 2.61 0.26 18.84 10.0
HC2 Digene 344 0.24 0.21 1.04 0.50 0.23 1.20 4.16 1.70 0.38 11.89 10.0
HC2 Digene 405 0.59 0.24 1.28 0.47 0.23 1.38 4.53 2.05 0.51 15.77 10.0
HC2 Digene 31 0.34 0.25 1.69 0.36 0.31 2.43 6.36 2.83 0.45 34.82 10.0
HC2 Digene 315 0.40 0.70 1.12 0.40 0.30 1.20 4.50 2.40 0.50 15.20 10.0
HC2 Digene 147 0.56 0.47 1.72 0.28 0.55 1.38 6.67 2.68 0.46 18.40 10.0
HC2 Digene 407 0.57 0.52 1.14 0.77 0.46 1.60 3.86 2.29 0.45 13.97 10.0
HC2 Digene 11 0.15 0.26 1.02 0.20 0.13 1.13 3.51 1.63 0.19 12.85 10.0
HC2 Digene 230 0.23 0.19 1.06 0.18 0.20 1.22 4.09 1.82 0.22 15.56 10.0
HC2 Digene 471 0.16 0.14 1.43 0.15 0.17 1.36 5.67 2.70 0.18 18.75 10.0
HC2 Digene NRL PV 0.35 0.33 1.67 0.23 0.39 1.73 7.27 2.64 0.35 18.63 10.0
EQA – External Quality Assurance, HPV – Human Papillomavirus, * – error caused by the low sensitivity of the detection method, ** –
probable contamination of samples, HCT – Hybrid Capture 1 HPV test (Digene), HC2 – Hybrid Capture 2 HPV test (Digene), LR – low
risk, HR – high risk, RLU/CO – relative light units/cut-off, ND – not done, NRL PV – National reference laboratory for papilloma-
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TABLE 2


























HC2 Digene 11 24.43 0.15 0.11 3.79 20.76 0.13 0.11 0.11 0.12 6.51 10.0
HC2 Digene 13 24.60 0.25 0.32 4.41 24.18 0.23 0.19 0.15 0.15 6.43 10.0
HC2 Digene 31 29.23 0.15 0.10 4.61 30.53 0.18 0.11 0.13 0.12 7.83 10.0
HC2 Digene 79 30.46 0.12 0.08 4.76 30.74 0.13 0.11 0.09 0.08 7.63 10.0
HC2 Digene 115 27.31 0.16 0.16 4.09 23.01 0.16 0.14 0.15 0.12 7.15 10.0
HC2 Digene 118 28.83 0.15 0.11 4.54 27.00 0.15 0.10 0.09 0.10 6.47 10.0
HC2 Digene 156 29.49 0.16 0.11 4.43 22.56 0.36 0.13 0.13 0.18 5.53 10.0
HC2 Digene 165 29.30 0.26 0.13 4.98 29.80 0.21 0.15 0.20 0.14 6.94 10.0
HC2 Digene 192 28.71 0.10 0.09 4.51 25.35 0.08 0.10 0.08 0.10 6.10 10.0
HC2 Digene 230 18.02 0.79 0.46 2.47 18.91 0.75 0.55 0.46 0.43 4.74 10.0
HC2 Digene 315 26.70 0.10 0.10 3.60 27.90 0.20 0.10 0.10 0.10 5.60 10.0
HC2 Digene 325 30.36 0.19 0.12 4.54 31.74 0.18 0.14 0.14 0.13 8.27 10.0
HC2 Digene 344 27.37 0.35 0.11 3.56 29.95 0.18 0.21 0.15 0.47 6.33 10.0
HC2 Digene 354 20.68 0.10 0.08 3.51 19.98 0.10 0.12 0.06 0.10 2.85 10.0
HC2 Digene 369 18.22 0.54 0.63 2.95 16.47 0.49 0.38 0.54 0.38 4.45 10.0
HC2 Digene 371 28.88 0.16 0.07 4.22 26.02 0.25 0.10 0.11 0.12 6.73 10.0
HC2 Digene 373 3.16 0.16 0.15 4.40 26.60 0.17 0.16 0.17 0.16 6.69 10.0
HC2 Digene 407 25.00 ND ND ND 31.00 ND ND ND ND 6.00 10.0
HC2 Digene 585 27.46 0.26 0.45 4.38 23.70 0.27 0.23 0.24 0.18 7.45 10.0
HC2 Digene 734 29.37 0.16 0.09 4.85 27.72 0.14 0.09 0.13 0.10 7.17 10.0
HC2 HR Digene 584 – 0.19 – 4.45 – 0.14 – 0.12 – 7.38 10.0
HC2 HR Digene 736 – 0.13 – 5.15 – 0.14 – 0.21 – 8.21 10.0
HC2 Digene NRL PV1 28.50 0.13 0.10 4.65 29.50 0.12 0.10 0.13 0.15 7.59 10.0













































16 poz poz neg neg** poz neg neg neg neg poz 9.0
Amplicor HPV
Test Roche
365 – poz – poz – neg – neg – poz 10.0
Amplicor HPV
Test Roche
716 – neg* – poz – neg – neg – poz 10.0
Amplicor HPV
Test Roche
NRL PV – poz – poz – neg – neg – poz 10.0
“in house” PCR
GP5+/6+bio
NRL PV HPV 6 HPV 33 0 HPV 16 HPV 6 0 0 0 0 HPV 16, 39 10.0
EQA – External Quality Assurance, HPV – Human Papillomavirus, * – borderline concentration of HPV DNA, ** – error, LR – low
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methods for assessment of EQA in our laboratory, this
discrepancy was obvious and we sent our comments to
the producers of EQA, which resulted in the change of
the HPV DNA amount in the ECQ in 2005.
Conclusion
EQA in medical microbiology in the Czech Republic is
well organized. It is coordinated by AD-CEM of the Na-
tional Institute of Public Health in Prague. First samples
were sent out in 1993. EQA for HPV has been available
since 2000 and in 2006, 29 laboratories participated in
this programme. As has been shown for other prog-
rammes, the EQA for HPV has proved to be useful, help-
ing to improve the accuracy of analyses and contributing
to the standardization of methods of HPV DNA testing.
EQA for HPV has been well received by routine laborato-
ries, demonstrated by a high number of these institu-
tions voluntarily participating in EQA.
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OSIGURANJE KVALITETE TESTOVA NA HUMANI PAPILOMAVIRUS (HPV)
S A @ E T A K
Vanjska provjera kvalitete (EQA, od engl. External Quality Assurance) je dobro organizirana u medicinskoj mikro-
biologiji u Republici ^e{koj. Koordinirana je od Odjela za akreditaciju centra za epidemiologiju i mikrobiologiju (AD-
-CEM, od engl. Accreditation Department of the Centre of Epidemiology and Microbiology) Nacionalnog instituta javnog
zdravstva u Pragu. Od 1993. godine, kada su prvi uzorci poslani vani, broj programa i uklju~enih laboratorija je naglo
narastao. EQA je za humani papilomavirus (HPV) bila u upotrebi od 2000. godine. Kako je bilo prikazano za druge
programe, EQA se pokazala korisnom za HPV, poma`u}i tako pove}anju to~nosti analiza i doprinose}i standardizaciji
metoda HPV-DNK-testova. EQA je dobro prihva}ena za HPV od strane laboratorija koji vr{e rutinske analize, na {to
ukazuje dobrovoljno sudjelovanje velikog broja ovih institucija u EQA.
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TABLE 3
























2000 22 21 11 10 – – – –
2001 25 24 8 16 – – – –
2002 28 22 3 19 – – – –
2003 27 21 2 18 – 1 – –
2004 25 23 1 19 – 2 – 1
2005 25 23 – 19 – 2 1 1
2006 29 28 – 20 2 3 2 1
EQA – External Quality Assurance, HPV – Human Papillomavirus, HCT – Hybrid Capture 1 HPV test (Digene), HC2 – Hybrid Cap-
ture 2 HPV test (Digene), HR – high risk, HPV INNO-LiPA – Line blot assay (Innogenetics), Amplicor HPV Test – Polymerase chain
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